Obseva (OBSV) Stock Rating Reaffirmed by BMO Capital Markets
Several other research firms also recently commented on OBSV. HC Wainwright set a $25.00 target price on Obseva and gave the stock a buy rating in a report on Monday, October 30th. Zacks Investment Research downgraded Obseva from a buy rating to a hold rating in a report on Tuesday, December 19th. Credit Suisse Group reissued a buy rating and issued a $18.00 target price (up from $16.00) on shares of Obseva in a report on Tuesday. Leerink Swann boosted their target price on Obseva from $17.00 to $18.00 and gave the stock an outperform rating in a report on Tuesday. Finally, Royal Bank of Canada reissued a buy rating and issued a $22.00 target price on shares of Obseva in a report on Thursday, November 2nd. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock presently has a consensus rating of Buy and an average price target of $19.67.
Shares of Obseva (NASDAQ OBSV) opened at $14.30 on Tuesday. Obseva has a 1-year low of $5.00 and a 1-year high of $15.81.
COPYRIGHT VIOLATION NOTICE: This piece was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://www.watchlistnews.com/obseva-obsv-stock-rating-reaffirmed-by-bmo-capital-markets/1904643.html.
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of endometriosis (phase 2b of clinical trials) and uterine fibroids (phase 3 of clinical trials); Nolasiban (OBE001), an oral oxytocin receptor antagonist undergoing phase 3 of clinical trials, with the potential to inhibit uterine contractions at the time of embryo transfer, thereby enhancing embryo implantation during assisted reproductive technologies (ART), and OBE022, an oral and selective prostaglandin F2 alpha (PGF2a) receptor antagonist designed to control preterm labor (phase 2a of clinical trials).
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.